Literature DB >> 29617694

Soluble Receptor for Advanced Glycation End Products (sRAGE) is Up-Regulated in Multiple Sclerosis Patients Treated with Interferon β-1a.

Mahnoosh Rahimi1, Sarah Saadat Aghabozorg Afjeh1, Mir Davood Omrani1,2, Shahram Arsang-Jang3, Maziar Ganji1, Rezvan Noroozi4, Mohammad Taheri1,2, Soudeh Ghafouri-Fard1,2.   

Abstract

BACKGROUND/AIMS: Multiple sclerosis (MS) is a chronic inflammatory disorder of the central nervous system. Considering the role of immune system in its pathogenesis, researchers have focused on evaluation of the expression of immune-related genes or proteins in MS patients. Among proteins whose participation in inflammatory process has been documented is the receptor for advanced glycation end products (RAGE).
METHODS: In the present study, we compared RAGE transcript levels by means of quantitative real-time PCR as well as the serum level of soluble RAGE (sRAGE) by means of enzyme- linked immunosorbent assay (ELISA) in 50 IFNβ-1a responsive relapsing-remitting MS patients when compared with age and sex-matched healthy subjects.
RESULTS: Elevated expression of RAGE as well as higher levels of sRAGE were detected in IFN-β responsive MS patients compared with the controls. A significant inverse correlation between sRAGE plasma concentrations and the expanded disability status scale (EDSS) was also detected in which each unit of increase in sRAGE level resulted in a 0.308 unit decrease in EDSS.
CONCLUSION: Considering the stable clinical state of the MS patients in this study and their response to IFNβ-1a, the elevated levels of sRAGE in patients compared with healthy subjects could be related to the effects of this kind of treatment.
© 2018 The Author(s). Published by S. Karger AG, Basel.

Entities:  

Keywords:  Multiple sclerosis; sRAGE

Mesh:

Substances:

Year:  2018        PMID: 29617694     DOI: 10.1159/000488622

Source DB:  PubMed          Journal:  Cell Physiol Biochem        ISSN: 1015-8987


  5 in total

1.  Expression Profile of Selected MicroRNAs in the Peripheral Blood of Multiple Sclerosis Patients: a Multivariate Statistical Analysis with ROC Curve to Find New Biomarkers for Fingolimod.

Authors:  Mohammad Mahdi Eftekharian; Alireza Komaki; Mehrdokht Mazdeh; Shahram Arsang-Jang; Mohammad Taheri; Soudeh Ghafouri-Fard
Journal:  J Mol Neurosci       Date:  2019-03-21       Impact factor: 3.444

2.  Down-regulation of ERMN expression in relapsing remitting multiple sclerosis.

Authors:  Behnaz Salek Esfahani; Jalal Gharesouran; Soudeh Ghafouri-Fard; Shahrzad Talebian; Shahram Arsang-Jang; Mir Davood Omrani; Mohammad Taheri; Maryam Rezazadeh
Journal:  Metab Brain Dis       Date:  2019-05-23       Impact factor: 3.584

Review 3.  Genetic and Molecular Biology of Multiple Sclerosis Among Iranian Patients: An Overview.

Authors:  Meysam Moghbeli
Journal:  Cell Mol Neurobiol       Date:  2019-09-03       Impact factor: 5.046

Review 4.  Role of RAGE in the Pathogenesis of Neurological Disorders.

Authors:  Judyta Juranek; Konark Mukherjee; Bernard Kordas; Michał Załęcki; Agnieszka Korytko; Kamila Zglejc-Waszak; Jarosław Szuszkiewicz; Marta Banach
Journal:  Neurosci Bull       Date:  2022-06-21       Impact factor: 5.271

5.  Evaluation of S100A12 and Apo-A1 plasma level potency in untreated new relapsing-remitting multiple sclerosis patients and their family members.

Authors:  Mahsa Samangooei; Mojtaba Farjam; Masoud Etemadifar; Atefeh Taheri; Mohammad Hassan Meshkibaf; Bahram Movahedi; Zahra Niknam; Saam Noroozi
Journal:  Sci Rep       Date:  2022-02-09       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.